Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 1.00 |
| ▸ | MMP12 | P39900 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mk-3281 SCHEMBL3088843 | 1.00 | PRKCA (1.00) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| Mk-3281 SCHEMBL29399714 | 1.00 | PRKCA (1.00) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| Mk-3281 SCHEMBL31554854 | 1.00 | PRKCA (1.00) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| Mk-3281 SCHEMBL3086966 | 0.96 | PRKCA (0.92) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| Mk-3281 SCHEMBL3092945 | 0.96 | PRKCA (0.92) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| Mk-3281 SCHEMBL3085872 | 0.96 | PRKCA (0.92) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL2274295 | 0.93 | PRKCA (0.88) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL4210853 | 0.93 | PRKCA (0.86) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL14110751 | 0.91 | PRKCA (0.84) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL3095894 | 0.91 | PRKCA (0.84) | PRKCAMMP12NR1I2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795247-B2 | Tetracyclic indole derivatives as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-09-14 | — | — | US | claimed |
| US-20140328799-A1 | COMPOSITIONS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. | 2014-11-06 | — | — | US | disclosed |
| US-20140328799-A1 | COMPOSITIONS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140328799-A1 | COMPOSITIONS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, RNASE1, SERPINB1 | PRKCA 2494/4885MMP12 149/4885NR1I2 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.